- Home
- FCAP vs XFOR Comparison
FCAP vs XFOR Comparison
Compare FCAP & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCAP
- XFOR
- Stock Information
- Founded
- FCAP 1891
- XFOR 2014
- Country
- FCAP United States
- XFOR United States
- Employees
- FCAP N/A
- XFOR N/A
- Industry
- FCAP Savings Institutions
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FCAP Finance
- XFOR Health Care
- Exchange
- FCAP Nasdaq
- XFOR Nasdaq
- Market Cap
- FCAP 125.9M
- XFOR 84.3M
- IPO Year
- FCAP 1999
- XFOR N/A
- Fundamental
- Price
- FCAP $44.10
- XFOR $2.96
- Analyst Decision
- FCAP
- XFOR Strong Buy
- Analyst Count
- FCAP 0
- XFOR 3
- Target Price
- FCAP N/A
- XFOR $34.17
- AVG Volume (30 Days)
- FCAP 4.0K
- XFOR 1.6M
- Earning Date
- FCAP 10-24-2025
- XFOR 11-12-2025
- Dividend Yield
- FCAP 2.67%
- XFOR N/A
- EPS Growth
- FCAP 9.31
- XFOR N/A
- EPS
- FCAP 3.93
- XFOR N/A
- Revenue
- FCAP $44,673,000.00
- XFOR $32,774,000.00
- Revenue This Year
- FCAP N/A
- XFOR $1,313.84
- Revenue Next Year
- FCAP N/A
- XFOR N/A
- P/E Ratio
- FCAP $11.06
- XFOR N/A
- Revenue Growth
- FCAP 9.48
- XFOR 5721.31
- 52 Week Low
- FCAP $28.50
- XFOR $1.35
- 52 Week High
- FCAP $53.85
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- FCAP 67.66
- XFOR 48.17
- Support Level
- FCAP $42.77
- XFOR $3.08
- Resistance Level
- FCAP $44.04
- XFOR $3.79
- Average True Range (ATR)
- FCAP 0.78
- XFOR 0.45
- MACD
- FCAP 0.34
- XFOR -0.12
- Stochastic Oscillator
- FCAP 100.00
- XFOR 0.01
About FCAP First Capital Inc.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.